Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy

JAMA Network Open 2026 Open access

Read full text
Authors: Denis Sauré, Juan Pablo Torres, Marcel Goić, Charles Thraves, Jorge M. Pacheco, Javiera Burgos, Amal Zgheib, Felipe Del Solar, Ignasi Neira, Miguel O’Ryan, Leonardo J. Basso
DOI: 10.1001/jamanetworkopen.2026.6042
Cited by: 1
References: 19

Abstract

Importance: Nirsevimab is highly effective in preventing respiratory syncytial virus (RSV) infection in healthy infants. Evidence among infants at higher risk of severe RSV disease, such as those born preterm or with congenital heart disease (CHD), remains limited to clinical settings. Objective: To evaluate the association of nirsevimab with the prevention of RSV-related hospitalizations among at-risk infants after implementation of a universal immunization strategy in Chile. Design, Setting, and Participants: This case-control study used nationwide health registries of all public and private hospitals in Chile during the 2024 RSV season following the launch of a universal RSV immunization program with nirsevimab. The case group included at-risk infants born preterm (gestational age

Fields of Study & Subjects

Respiratory viral infections research Immunodeficiency and Autoimmune Disorders Pneumonia and Respiratory Infections

Publication details

Journal / source
JAMA Network Open
Publisher
American Medical Association (AMA)
Volume
9
Issue
4
Pages
e266042–e266042
Publication date
10 April 2026
Language
EN